OR-NIKE
5.2.2020 20:02:11 CET | Business Wire | Press release
Today, NIKE, Inc. (NYSE: NKE), unveiled breakthrough innovation for athletes competing in the Tokyo 2020 Games, including footwear designed to provide runners with a measurable performance benefit for a new era of competition. The NEXT% platform, introduced by barrier-breaking marathoner Eliud Kipchoge, will now expand into new disciplines following its unparalleled success in distance running.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200205005708/en/
Ahead of the hottest Games on record, Nike also debuted progressive new collections featuring sustainable materials for all athletes. As the growing climate emergency continues to disrupt competition and training, Nike’s sustainable innovations signal the brand’s commitment to helping protect the future of the planet – and, consequently, the future of sport. Highlights include our most sustainably designed medal stand uniform in Team USA history, footwear built predominantly from recycled waste and lifestyle apparel that embraces the goal of a zero-carbon future.
“At Nike, we see sport’s greatest stage as our biggest opportunity to show the world what’s possible,” said NIKE, Inc. President and CEO John Donahoe. “After all, what’s at stake isn’t just records, but the future of sport itself. In Tokyo, we’ll help the world’s best reach new levels of performance with our revolutionary platform, while sharing real solutions for the barriers all athletes face under rapidly changing climate conditions.”
- Team USA Medal Stand Collection [link ] : This summer, Team USA will prove the power of sustainability during medal ceremonies. In Tokyo, U.S. medalists will take the podium in iconic Windrunner jackets reengineered with 100% recycled polyester, pants featuring 100% recycled nylon and recycled-rubber Nike Grind trim and the Nike Air VaporMax 2020, constructed with recycled manufacturing material and precision-knit uppers for minimal waste.
- Nike Air Zoom Alphafly NEXT% [link ] : Call it the ultimate test run: when Eliud Kipchoge broke the two-hour marathon barrier in Vienna this past October, he was wearing a prototype of the Nike Air Zoom Alphafly NEXT%. In Summer 2020, Nike’s newest race-day shoe makes its official debut with two new Nike Air Zoom pods, additional foam, an updated carbon fiber plate and an ultra-breathable upper – all adding up to improved cushioning and running economy.
- Nike Air Zoom BB NXT [link ]: Nike Basketball's new Air Zoom BB NXT is engineered to be as light and responsive as possible. With a new Nike Air Zoom pod system, exposed Nike React foam and a thin plate positioned above the foam, the shoe provides athletes with lightweight strength, optimized impact protection and outstanding energy return.
- Nike SB Skateboarding Kits [link ] : For skateboarding’s debut on this summer’s global stage, Nike SB will introduce kits on the forefront of sustainable design. Athletes representing Team USA, France and Brazil will compete in uniforms designed with 100% recycled polyester, pattern efficiency for minimal waste and bright, bold styling (crafted in collaboration with Dutch artist Parra) to celebrate each nation’s unique sport culture.
- Space Hippie [link ] : In addition to product developed for athletes participating in the Tokyo 2020 Games, Nike will launch this spring an exploratory footwear collection that redefines what’s possible with sustainable product design. Space Hippie is constructed by transforming scrap material from factory floors – what Nike’s design teams have called “space junk” – into a radical expression of circular design. Every detail of the Space Hippie capsule collection, from material choices to methods of make to packaging, was chosen with consideration for its environmental impact, adding up to Nike’s lowest carbon footprint footwear.
NIKE, Inc., based near Beaverton, Oregon, is the world’s leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE, Inc.’s earnings releases and other financial information are available on the Internet at http://investors.nike.com . Individuals can also visit http://news.nike.com and follow @NIKE.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005708/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
